FierceBiotech1 天
AstraZeneca CEO defends 'fantastic' Alexion buyout in face of $753M hit from dropped drug
Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...
FierceBiotech3 天
Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates
Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...